Key Points
- MoonLake director BVF Partners P/Il sold 3,750,000 shares on March 31 at an average price of $16.79, netting about $62.96 million and cutting their stake to 1,039,238 shares — a 78.30% decrease — per an SEC filing.
- MoonLake is a clinical‑stage biopharma with a $1.25B market cap and recent negative EPS (‑$0.92); analysts have issued several upgrades but the consensus rating remains "Hold" with a $23.08 target.
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) Director Bvf Partners P/Il sold 3,750,000 shares of MoonLake Immunotherapeutics stock in a transaction that occurred on Tuesday, March 31st. The stock was sold at an average price of $16.79, for a total value of $62,962,500.00. Following the sale, the director owned 1,039,238 shares in the company, valued at $17,448,806.02. This represents a 78.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
MoonLake Immunotherapeutics Stock Performance
Shares of MLTX opened at $17.36 on Friday. The firm has a market cap of $1.25 billion, a price-to-earnings ratio of -4.93 and a beta of 1.19. The company has a quick ratio of 9.27, a current ratio of 9.27 and a debt-to-equity ratio of 0.24. The business's 50 day moving average is $16.94 and its two-hundred day moving average is $16.89. MoonLake Immunotherapeutics has a 52-week low of $5.95 and a 52-week high of $62.75.
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.92) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.92). During the same quarter last year, the company posted ($0.72) EPS. Analysts forecast that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.
Analyst Ratings Changes
MLTX has been the subject of several recent analyst reports. Needham & Company LLC raised their price objective on shares of MoonLake Immunotherapeutics from $20.00 to $25.00 and gave the stock a "buy" rating in a report on Monday, February 23rd. HC Wainwright upped their target price on shares of MoonLake Immunotherapeutics from $32.00 to $40.00 and gave the company a "buy" rating in a research note on Monday, March 2nd. Wolfe Research upgraded MoonLake Immunotherapeutics from an "underperform" rating to an "outperform" rating and lifted their price target for the stock from $12.00 to $24.00 in a research note on Monday, March 23rd. Rothschild & Co Redburn raised MoonLake Immunotherapeutics from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $12.00 to $40.00 in a report on Thursday, March 19th. Finally, UBS Group set a $24.00 price objective on MoonLake Immunotherapeutics in a research note on Friday, January 9th. Nine investment analysts have rated the stock with a Buy rating, four have given a Hold rating and three have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, MoonLake Immunotherapeutics has a consensus rating of "Hold" and a consensus target price of $23.08.
View Our Latest Stock Analysis on MLTX
Hedge Funds Weigh In On MoonLake Immunotherapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in MLTX. Millennium Management LLC grew its holdings in MoonLake Immunotherapeutics by 3,343.2% in the 1st quarter. Millennium Management LLC now owns 344,320 shares of the company's stock worth $13,453,000 after buying an additional 334,320 shares in the last quarter. Geode Capital Management LLC boosted its position in MoonLake Immunotherapeutics by 0.9% during the 2nd quarter. Geode Capital Management LLC now owns 59,553 shares of the company's stock worth $2,809,000 after acquiring an additional 559 shares during the period. JPMorgan Chase & Co. grew its stake in shares of MoonLake Immunotherapeutics by 4,584.5% in the second quarter. JPMorgan Chase & Co. now owns 39,397 shares of the company's stock worth $1,860,000 after purchasing an additional 38,556 shares in the last quarter. Legal & General Group Plc grew its stake in shares of MoonLake Immunotherapeutics by 7.3% in the second quarter. Legal & General Group Plc now owns 20,905 shares of the company's stock worth $987,000 after purchasing an additional 1,425 shares in the last quarter. Finally, Schroder Investment Management Group acquired a new position in shares of MoonLake Immunotherapeutics during the second quarter valued at $915,000. 93.85% of the stock is currently owned by institutional investors and hedge funds.
About MoonLake Immunotherapeutics
(
Get Free Report)
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
